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Abstract
Infection with the common pathogen Chlamydophila pneumoniae (Cpn, previously Chlamydia
pneumoniae) has a high prevalence in patients suffering from arteriosclerosis and may trigger or
contribute to heart disease. In mice, CD8-positive T cells are critical for the eradication of the infection
and the development of immune memory against Cpn. Although several H2-class I epitopes have
been described, no HLA-class I-associated peptides from Cpn are known. In order to define HLA-
A*0201 epitopes from Cpn, we focused on the bacterial heat shock proteins (HSP) 60 and 70 which are
known to be recognized by the immune system. Using epitope prediction, peptide binding studies and
peptide-specific CTLs from HLA-A2 transgenic mice, we could define a potential HSP-70-derived
epitope. The study of PBMCs from Cpn-infected individuals using fluorescent MHC tetramers revealed
that some patients have CD81 T cells capable of recognizing the Cpn HSP-70 HLA-A*0201 epitope.
Our studies pave the way to the immunomonitoring of the anti-Cpn CTL immune response present in
patients suffering from different diseases potentially linked to Cpn or anti-Cpn immunity.
Introduction
Chlamydophila pneumoniae (Cpn, formerly Chlamydia pneu-
moniae) is a common intracellular pathogen that is estimated
to infect nearly every human being several times during
lifetime (1). Cpn infections and re-infections are in the vast
majority of cases not associated with clinical signs. Yet, in rare
cases, Cpn is the cause of community-acquired pneumoniae,
bronchitis, pharyngitis and sinusitis. Importantly, Cpn infection
can be persistent (2) and may be associated with chronic
diseases such as multiple sclerosis (3), asthma (4) and
coronary heart diseases (review by Taylor-Robinson and
Thomas) (5). Seroepidemiological studies (6), animal experi-
ments (7) and detection of Cpn within arteriosclerotic plaque
tissues (8) suggest that Cpn infections may participate in the
development of arteriosclerosis. Consequently, a prophylactic
or therapeutic vaccine that would be efficient in the prevention
or clearance of a persistent Cpn infection may be of great
interest. In mice, the eradication of Cpn as well as the anti-Cpn
memory immunity require CD8-positive CTL (9). Accordingly,
vaccine formulations able to trigger CTLs such as DNA-based
vaccines can partially protect against Cpn infection (10, 11).
Among all proteins expressed by Cpn, surface molecules
(especially OMP2) and heat shock proteins (HSP) seem to be
relevant antigens, shown to be naturally recognized during
infection (12, 13). Wizel et al. reported the identification of
mouse H2-class I epitopes from these Cpn proteins among
others. Because HSP-70 (12, 14, 15) and HSP-60 (12, 15)
are naturally recognized during Cpn infection and because
of the link between immune recognition of Cpn HSP and
Cpn-associated pathologies (16, 17), we focused on these
chaperones to discover human MHC class I-associated
epitopes derived from Cpn. Since HLA-A*0201 is one of
the most prevalent human class I molecules, we predicted
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potential HLA-A*0201-associated epitopes from Cpn HSP-60
and HSP-70. Using CTLs derived from HLA transgenic mice
and fluorescent MHC class I tetramers, we found that one
HSP-70-derived epitope presented by HLA-A*0201 is recog-
nized by human CTLs. Our discovery opens the door to larger
studies where the presence of such CTLs could be compared
with the level of Cpn infection and the onset of diseases such
as arteriosclerosis, multiple sclerosis, Alzheimer disease,
asthma, etc.
Methods
Tumor cell lines
HeLa cells were transfected with a plasmid coding for
a chimeric HLA-A*0201 molecule containing the a3, trans-
membrane and cytoplasmic domains of H-2Db to give HeLa/
A2A2Db transfectants (18). Cells were grown in RPMI 1640
enriched with 10% FCS, 2 mM L-glutamine and 1% penicillin/
streptomycin (Life Technologies, Inc.) supplemented at
1 mg ml1 G418 (Life Technologies, Inc.).
Animals
Six- to twelve-week old HHDII mice were bred in our animal
facility. The local animal ethics committee of Tu¨bingen gave its
approbation for peptide vaccination of mice (number IM/98).
Patients
The study was made after acceptation of the project by the
ethic commission of Tu¨bingen: ‘Untersuchung der T-Zell-
vermittelten Immunantwort gegen synthetische Peptide aus
Chlamydia pneumoniae (Cpn) Antigenen bei infizierten
Patienten mit koronarer Herzerkrankung (KHK)’ (study number
125/2002V). The patients were admitted to the Department of
Medicine III (Cardiology) of the University Hospital Tu¨bingen
for the diagnosis and treatment of coronary heart disease.
Upon their agreement (documented by their signature of a
letter describing the goals of the research), 55 ml of blood was
drawn from the patients: 50 ml in heparinized syringes and
5 ml in syringes without heparin. The heparinized blood was
overlaid on a Ficoll solution for the preparation of PBMCs.
PBMCs were frost in FCS 10% dimethyl sulfoxide (DMSO) at
10 million cells per aliquot and stored in liquid nitrogen. The
serum was recovered from non-heparinized blood and kept
at 80C. Each patient was typed for HLA-A*0201 using
FACS analysis of 0.5 million fresh PBMCs stained with the
mAb BB7.2 (American Type Culture Collection, Manassas, VA,
USA). The detection of anti-Cpn antibodies in sera was
performed using the ELISA kit from Medac GmbH, according
to the manufacturer’s instructions.
Epitope prediction
Prediction of potential HLA-A*0201 ligands was carried out as
described (24). Briefly, proteins were screened against a
matrix pattern, which evaluates every amino acid within
nonamer or decamer peptides fitting the HLA-A*0201 motif.
Anchor residues are given values of 1; other residues, 0–1,
reflect amino acid preferences for certain positions within
the peptide. Such motif predictions are available using the
database SYFPEITHI (http://www.uni-tuebingen.de/uni/kxi/).
Peptides
Peptides were synthesized in an automated peptide synthe-
sizer 432A (Applied Biosystems, Foster City, CA, USA)
following the 9-fluorenylmethyloxycarbonyl/tert-butyl strategy.
After removal from the resin by treatment with trifluoroacetic
acid : phenol : ethanedithiol : thioanisole : water (90 : 3.75 :
1.25 : 2.5 : 2.5 by volume) for 1 or 3 h (arginine-containing
peptides), peptides were precipitated from methyl-tert-butyl
ether, washed once with methyl-tert-butyl ether and twice with
diethyl ether and re-suspended in water before lyophilization.
Synthesis products were analyzed by HPLC (System Gold;
Beckman Instruments, Fullerton, CA, USA) and matrix-assisted
laser desorption/ionization time of flight mass spectrometry
(G2025A; Hewlett-Packard, Palo Alto, CA, USA). Peptides of
<80% purity were purified by preparative HPLC.
Peptide binding assay
T2 cells were used for binding studies. A 1 mM peptide stock
solution in PBS 10% DMSO was made, and cells were
incubated with the peptide at a final concentration of 10 lM,
1 lM or 0.1 lM in RPMI 1640 overnight at 37C. HLA surface
expression was monitored after staining with the primary
antibody BB7.2 and a FITC-coupled goat anti-mouse
(GAM) IgG (Dianova, Hamburg, Germany) on a FACSCalibur
cytometer (Becton-Dickinson, San Jose, CA, USA). Figure 1
presents the results of these studies:  means no binding
detectable at any peptide concentration, + means binding
detectable at only the highest peptide concentration (10 lM),
++ means binding detectable starting at the 1 lM peptide
concentration and +++ means binding detectable starting at
the 0.1 lM peptide concentration.
Generation of mouse CTLs
HHD mice (18) were injected subcutaneously in the neck with
25 lg of synthetic peptides mixed with 25 lg of the Hepatitis B
virus core128–140 helper epitope (25) and 50 ll of Titermax
(Sigma). Ten days later, spleens were removed, and splen-
ocytes were put in culture in 10 ml of Iscove’s modified
Dulbecco’s medium supplemented with 10% FCS, 2 mM
L-glutamine, 1% penicillin/streptomycin (Life Technologies,
Inc.), 50 lg ml1 gentamicin (Life Technologies, Inc.), 5 3
105 M b-mercaptoethanol and 1 mM sodium pyruvate
(Sigma). Peptide was added at a final concentration of 1 lM.
Three days later, 25 units of recombinant IL-2 (Proleukin;
Chiron) were added. At day 6, the cytotoxicity of the cultures
was tested on 5000 unloaded or peptide-loaded 51Cr-labeled
HLA-A2-positive target cells. CTL cultures exhibiting detect-
able peptide-specific cytotoxicity were re-stimulated weekly
using 2 3 107 million peptide-loaded (1 lM peptide for 1 h),
freshly irradiated (200 Gy) HHD splenocytes. Long-term
cultures were used for intracellular cytokine staining.
Infection of cells with Cpn
Cells were infected at 1 infectious unit per cell as described (26).
The efficiency of infection was controlled 24 h after infection
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using the following method. The cells were fixed on a cover slip
for 10 min in PFA 2% in PBS. After washing, the extracellular
bacteria were stained using a mouse monoclonal anti-Cpn and
a secondary GAM-FITC antibody. After washing, cells were
permeabilized with Triton 2% in PBS for 4 min at room
temperature. Then, cells were incubated again with the anti-
Cpn antibody and a secondary GAM-Cy3 antibody. Cover slips
were analyzed by confocal microscopy. Inclusion bodies
appeared blue, whereas free bacteria outside the cells
appeared green.
Intracellular cytokine staining
Mouse CTL lines were co-incubated overnight with infected or
non-infected target cells (24–36 h after infection) in a medium
supplemented with GolgiStop (Pharmingen, San Diego, CA,
USA). Then, cells were permeabilized and stained using the
Cytofix/Cytoperm Plus kit and CD4 FITC, anti-IFN-c PE, and
CD8 CyC antibodies, according to the manufacturer’s recom-
mendations (BD-Pharmingen, Heidelberg, Germany). FACS
analysis was performed using a FACSCalibur cytometer
(Becton-Dickinson). Data in Fig. 2 show the IFN-c and CD8
expression in gated CD4-negative lymphocytes.
Staining of PBMCs with HLA–peptide tetrameric
complexes
PBMCs were defrosted and kept at 5 million cells ml1 for
more than 1 week in X-Vivo15 medium (Bio Whittaker, Belgium)
supplemented with 10 lM Cpn HSP-70 ALAYGIDKV peptide
and 5 mM IL-7 (R&D Systems). At day 4, 10 U ml1 rIL-2
(Proleukin; Chiron) were added. MHC class I–peptide tetra-
meric complexes were produced as previously described
(27). In brief, the heavy chain was modified by deletion of
the transmembrane domain and COOH-terminal addition of
a sequence containing the BirA enzymatic biotinylation site. The
HLA-A2 heavy chains and b2-microglobulins were produced
using a prokaryotic expression system (pET/HLA-A2 plasmid
and bacteria provided by Paul Travers), purified and re-folded
in vitro by limiting dilution with the HLA-A*0201-binding peptide
derived from Cpn HSP-70 ALAYGIDKV. The re-folded com-
plexes were purified by gel filtration (Superdex 75, Pharmacia)
using fast protein liquid chromatography, biotinylated by BirA
(Avidity, Denver, CO, USA) in the presence of biotin (Sigma
Chemical), ATP (Sigma Chemical) and Mg2+ (Sigma Chemical).
The biotinylated product was separated from free biotin by gel
filtration using fast protein liquid chromatography. Tetramers
Fig. 1. Predicted HLA-A*0201 epitopes from Cpn HSP-60 and HSP-70. Using the SYFPEITHI algorithm potential HLA-A*0201 epitopes from Cpn
HSP-60 and HSP-70 were predicted. Only potential epitopes with a score>3.000 are listed. Under each peptide sequence, the sequence in italic
corresponds to the ortholog peptides in the human HSP proteins. The Cpn peptides presented were synthesized and tested in a T2 binding assay.
Column ‘Experimental binding’ indicates the affinity of the peptides: High affinity (+++: stabilization of HLA-A*0201 molecules at a concentration of
0.1 lM), intermediate affinity (++: stabilization of HLA-A*0201 molecules at a minimal concentration of 1 lM) and low affinity (+: stabilization of
HLA-A*0201 molecules at a minimal concentration of 10 lM) for HLA-A2 and peptide showing no binding capacity in this test (: no accumulation
of HLA-A2 molecules at the surface of T2 cells after overnight culture with up to 10 lM peptides). Each peptide showing binding capacity to HLA-
A*0201 was injected in HHDII mice. Immunogenic peptides (as detected after in vitro stimulation of splenocytes with peptides and cytotoxic
assays, data not shown) are indicated with ‘yes’ in the column ‘Immunogenicity in HHD mice’. ‘NT’ means that the peptides were not injected in
mice (showing no binding to HLA-A2 in the T2 assay).
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were made by mixing biotinylated protein complexes with
streptavidin–PE (Molecular Probes) at a molecular ratio of 4 : 1.
At days 6–10 of culture, cells were stained with MHC class I–
HLA-A*0201 tetramers: a mixture of two tetramers comprising
the PE-labeled Cpn HSP-70 tetramer and an antigen presenting
cell (APC)-labeled HLA-A*0201-tetramer containing the domin-
ant HLA-A*0201 epitope from CMV pp65 (28). Both tetramers
were incubated with 2 million PBMCs at a final concentration of
5 lg ml1 in a final volume of 100 ll of PBS 50% FCS and 2 mM
EDTA for 30 min at 4C. Then, CD19 FITC, CD4 FITC, CD8 PerCp
antibodies (all from BD-Pharmingen) were added in 100 ll PBS
50% FCS and 2 mM EDTA. The cells were incubated at 4C for
30 min and washed twice with PFEA (PBS with 2% FCS, 2 mM
EDTA) before fixation with PBS containing 1% formaldehyde.
Stained PBMCs were analyzed by four-color flow cytometry
(FACSCalibur, Becton-Dickinson). Data presented in Fig. 3
are gated on CD8-positive, CD19-negative and CD4-negative
cells.
Results and Discussion
Some predicted HLA-A*0201 epitopes from Cpn HSP-60
and HSP-70 bind HLA-A*0201
Using the algorithm SYFPEITHI (http://www.uni-tuebingen.
de/uni/kxi/), we predicted HLA-A*0201 epitopes from Cpn
HSP-60 and HSP-70 (Fig. 1). Peptides with a score >3.000
were synthesized: six potential epitopes for HSP-60 and four
potential epitopes for HSP-70. All these peptides are different
from their ortholog sequences in the human HSP-60 or HSP-70
(see sequence in italics in Fig. 1). Three of the HSP-60-
predicted epitopes have only one or two residues different
from the human sequence. These epitopes could be candi-
dates to support the postulated pathogenic cross-recognition
of human-derived peptides by immune cells directed against
Cpn (16). We used a T2 binding assay to measure the actual
binding of the predicted epitopes to HLA-A2. In this test, the
accumulation of HLA-A*0201 molecules at the cell surface
(recorded using indirect antibody staining and FACS analysis)
reflects the capacity of exogenous peptides to bind and
stabilize this class I molecule. While all four predicted epitopes
from HSP-70 were found to bind to HLA-A*0201, only one of
the six potential HSP-60 epitopes showed detectable binding
to HLA-A*0201. These five HLA-A*0201-binding peptides
were injected into HLA-A*0201 transgenic mice [H2 class I
deficient: HHDII mice (18)]. Two of the peptides (HSP-70
ALVRCIPTL and HSP-60 ALAYGIDKV) were immunogenic and
allowed the derivation of CTL lines capable to specifically kill
target cells expressing HLA-A2 and loaded with the respective
peptide (data not shown).
Mouse CTLs directed against Cpn HSP-predicted
epitopes do not specifically recognize Cpn-infected cells
In order to test whether the two candidate epitopes were
presented at the cell surface of Cpn-infected cells, we used
the transgenic human tumor cell line HeLa/A2A2Db (HeLa
transfected with the gene coding the chimeric A2A2Db
protein) (18). Such cells could be infected by Cpn as
confirmed by intracellular antibody staining and confocal
studies (data not shown). The infected or non-infected target
cells were co-incubated overnight with the two peptide-
specific CTLs derived from HHDII mice. The activation of the
CTLs was recorded using intracellular IFN-c staining and
FACS analysis. As shown in Fig. 2, the two CTL lines reacted to
the peptides loaded on HLA-A2-positive cells (lower two dot
plots ‘peptide’): 35.01 and 9.14% CD8-positive, IFN-c-positive
cells in the CTL lines specific for (Cpn HSP-60) ALVRCIPTL
and (Cpn HSP-70) ALAYGIDKV peptides, respectively. How-
ever, none of the CTL line was activated in the presence of
infected HeLa/A2A2Db cells (upper dot plot, infected HeLa/
A2A2Db). Apparently, in these cells, the two Cpn-derived
peptides could not be processed and presented by HLA-
A*0201. Since Cpn develops in vesicules similar to endo-
somes, we hypothesized that in tumor cells the proteins
produced from Cpn do not have access to the cytosol and
consequently cannot be processed by the MHC class I
presentation machinery (proteasome, transporter associated
with antigen processing-TAP-pumps). The optimal cell types
as far as transfer of antigens from endosomes to the cytosol is
concerned are dendritic cells (19). Thus, we tested the
presentation of the two predicted HLA-A*0201 epitopes at
the surface of infected mouse dendritic cells. Bone marrow-
derived dendritic cells (BM-DCs) were prepared from HHDII
mouse hind legs. Since Cpn infection is known to mature
dendritic cells (20), we used LPS-matured BM-DCs as
Fig. 2. Response of peptide-specific CTLs to Cpn-infected cells. HHD
mouse CTL lines specific for HSP-60 ALVRCIPTL or HSP-70 ALAY-
GIDKV peptides were co-incubated overnight with Cpn-infected HeLa/
A2A2Db cells, infected or non-infected BM-DCs from HHDII mice and
peptide-pulsed HeLa/A2A2Db cells. After permeabilization, cells were
stained for CD4, CD8 and INF-c. The numbers indicate the percentage
of CD8-positive, INF-c-positive cells among gated CD4-negative cells.
594 HLA-A2-restricted T cells against Cpn
negative controls in the assay. Infection of BM-DCs was
confirmed by intracellular detection of Cpn (data not shown).
As shown in Fig. 2, the HSP-60-derived peptide-specific CTL
lines were not activated by Cpn-infected autologous BM-DCs
(‘infected HHD DCs’). Looking for H2-class I epitopes, neither
our group (13) nor Wizel et al. (15) could identify HSP-60-
derived CTL epitopes. This family of proteins is highly
conserved between species and immune tolerance may
prevent the development of CTLs against HSP-60. The HSP-
70-derived peptide-specific CTL line was activated by
infected and also by non-infected BM-DCs. Thus, a peptide
that can be recognized by this CTL line is expressed at the
surface of BM-DCs. In this situation, the actual presentation of
the Cpn HSP-70 potential epitope could not be addressed
using our in vitro system. Nevertheless, this experiment
indicates that CTLs specific for a Cpn-peptide can recognize
non-infected cells. Since a large number of evidences suggest
that some pathologies associated with Cpn infection, particu-
larly in arteriosclerosis, are due to cross-recognition by
immune cells of self and Cpn antigens (16, 17, 21, 22), we
decided to further investigate the presence of CTLs specific
for the (Cpn HSP-70) ALAYGIDKV potential epitope in the
blood of HLA-A2-positive heart disease patients.
Detection of CTLs that can recognize the (Cpn HSP-70)
ALAYGIDKV potential epitope in the blood of patients with
anti-Cpn antibodies
We produced HLA-A*0201 monomers folded around the HSP-
70 ALAYGIDKV peptide. The monomers were biotinylated,
purified and tetramerized with streptavidin–PE. Using these
fluorescent tetramers, we studied the presence of CTLs
capable of recognizing the HSP-70 ALAYGIDKV peptide in
the blood of patients. Blood samples were collected from 57
heart disease patients. We chose this population of patients
since people suffering from heart-related health problems are
known to have a high prevalence of Cpn infections (6).
Patients were typed for HLA-A2 using antibody staining
(BB7.2) of fresh PBMCs and checked for the presence anti-
Cpn immunity using sera. Twenty-six patients had detectable
anti-Cpn IgG antibodies and among those 13 had detectable
Fig. 3. MHC class I tetramer staining of in vitro cultured human PBMCs. PBMCs from 10 HLA-A2-positive, anti-Cpn antibody-positive (HLA-A2+
Cpn AB+) and 7 HLA-A2-positive and anti-Cpn antibody-negative (HLA-A2+ Cpn AB) cells were cultured for 1 week in the presence of the Cpn
HSP-70 ALAYGIDKV peptide and stained with two fluorescent HLA-A*0201 tetramers: one folded around the Cpn HSP-70 ALAYGIDKV peptide
(PE labeled) and one folded around the CMV pp65 NLVPMVATV peptide (APC labeled). The numbers indicate the percentage of CD8-positive,
Cpn HSP-70 ALAYGIDKV tetramer-positive cells among gated CD4-negative, CD19-negative cells. Those cells are not stained by the control APC
tetramer, indicating that the recognition by the PE tetramer is specific.
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anti-Cpn IgA antibodies. PBMCs from all patients were
conserved in liquid nitrogen. Defrosted PBMCs from all HLA-
A2+ Cpn AB+ patients (n = 10) and from HLA-A2+ Cpn AB
patients (n = 7) were cultivated for 1 week in medium
containing the HSP-70 ALAYGIDKV peptide before tetramer
staining and FACS analysis (such in vitro amplification of CTL
precursors allows a more sensitive study of the specific CTLs).
The results of these studies are shown in Fig. 3 (dot plots gated
on CD8-positive, CD4-negative and CD19-negative cells). We
could never detect tetramer-positive CD8-positive cells in the
cultured PBMCs from HLA-A*0201-negative patients (whether
their sera were positive or negative for anti-Cpn antibodies;
data not shown) or in the cultured PBMCs from HLA-A*0201-
positive patients having no detectable IgA or IgG against Cpn
in their sera (n = 7 patients). On the contrary, three cultures
made from the PBMCs of HLA-A2-positive patients having
detectable antibodies against Cpn (n = 10 patients) contained
detectable CD8+ cells recognized by the fluorescent HLA-
A*0201 tetramer folded around the Cpn HSP-70 ALAYGIDKV
peptide. The cells recognized by the PE-labeled tetramer
folded around the Cpn HSP-70 ALAYGIDKV peptide were not
co-stained by the control APC-labeled tetramer (HLA-A*0201
folded around a CMV pp65 peptide). Thus, the PE-positive
cells were specific for the Cpn HSP-70 ALAYGIDKV peptide.
This analysis shows that CTLs capable of recognizing the Cpn
HSP-70 potential HLA-A*0201 epitope are present in the
blood of 30% (3 out of 10) of the patients infected with Cpn
(having antibodies against Cpn).
Some HLA-A2-positive patients (7 out of 10) having anti-
bodies against Cpn do not have CTL precursors specific for
the ALAYGIDKV peptide in frequencies high enough for
detection in our screening system. This may be due to the
fact that in these patients the frequency of such CTLs is too low
to be detected even after in vitro amplification. Besides, the
phenomenon of immunodominance may inhibit the recognition
of the ALAYGIDKV peptide when other immunodominant
peptides presented by HLA-class I molecules different from
HLA-A*0201 are available (23).
HeLa/A2A2Db cells infected with Cpn did not activate the
ALAYGIDKV-specific T cells. Thus, these tumor cells infected
in vitro do not process the epitope. In vivo, the precise cell types
(aortic epithelial cells or smooth muscle cells for example) that
are infected by Cpn may have different antigen-processing
capacities than HeLa and present the ALAYGIDKV epitope.
Besides, a cross-priming presentation whereby secreted Cpn
HSP-70 would be captured and processed by APCs may be
responsible for the triggering of the ALAYGIDKV-specific
T cells. These lymphocytes may recognize some yet non-
identified Cpn-infected cells. They may also recognize non-
infected cells (see the recognition of BM-DCs by anti-HSP-70
CTLs presented in Fig. 2). Thus, CTLs could participate in the
proposed ‘antigen mimicry’-mediated autoimmune patholo-
gies associated to bacterial infections (16, 17).
Using our results, the frequency of CTLs in the context
of Cpn-associated pathologies such as arteriosclerosis,
Alzheimer disease, multiple sclerosis, asthma, etc. (3, 4, 6)
can be evaluated and compared with the clinical status of the
patients. These studies could result in a better understanding
of the role of Cpn infection and anti-Cpn immune response in
chronic autoimmune diseases.
Acknowledgements
J.C. was supported by a ‘Fortune’ fellowship from the University of
Tu¨bingen. The project was also supported by a grant from the
National Genom Forschung Netzwerk (NGFN) of the Federal Ministry
for Research and Development (BMBF) and by the Karl Kuhn Stiftung.
Abbreviations
APC antigen presenting cell
BM-DC bone marrow-derived dendritic cell
Cpn Chlamydophila pneumoniae
DMSO dimethyl sulfoxide
GAM goat anti-mouse
HSP heat shock proteins
References
1 Kuo, C. C., Jackson, L. A., Campbell, L. A. and Grayston, J. T.
1995. Chlamydia pneumoniae (TWAR). Clin. Microbiol. Rev. 8:451.
2 Hammerschlag, M. R., Chirgwin, K., Roblin, P. M. et al. 1992.
Persistent infection with Chlamydia pneumoniae following acute
respiratory illness. Clin. Infect. Dis. 14:178.
3 Stratton, C. W. and Sriram, S. 2003. Association of Chlamydia
pneumoniae with central nervous system disease. Microbes Infect.
5:1249.
4 Hahn, D. L., Dodge, R. W. and Golubjatnikov, R. 1991. Association
of Chlamydia pneumoniae (strain TWAR) infection with wheezing,
asthmatic bronchitis, and adult-onset asthma. JAMA 266:225.
5 Taylor-Robinson, D. and Thomas, B. J. 2000. Chlamydia pneumo-
niae in atherosclerotic tissue. J. Infect. Dis. 181(Suppl. 3):S437.
6 Orfila, J. J. 1998. Seroepidemiological evidence for an association
between Chlamydia pneumoniae and atherosclerosis. Atheroscle-
rosis 140(Suppl. 1):S11.
7 Campbell, L. A., Rosenfeld, M. and Kuo, C. C. 2000. The role of
Chlamydia pneumoniae in atherosclerosis—recent evidence from
animal models. Trends Microbiol. 8:255.
8 Kuo, C. C., Shor, A., Campbell, L. A., Fukushi, H., Patton, D. L. and
Grayston, J. T. 1993. Demonstration of Chlamydia pneumoniae in
atherosclerotic lesions of coronary arteries. J. Infect. Dis. 167:841.
9 Penttila, J. M., Anttila, M., Varkila, K. et al. 1999. Depletion of CD8+
cells abolishes memory in acquired immunity against Chlamydia
pneumoniae in BALB/c mice. Immunology 97:490.
10 Penttila, T., Vuola, J. M., Puurula, V. et al. 2000. Immunity to
Chlamydia pneumoniae induced by vaccination with DNA vectors
expressing a cytoplasmic protein (Hsp60) or outer membrane
proteins (MOMP and Omp2). Vaccine 19:1256.
11 Svanholm, C., Bandholtz, L., Castanos-Velez, E., Wigzell, H. and
Rottenberg, M. E. 2000. Protective DNA immunization against
Chlamydia pneumoniae. Scand. J. Immunol. 51:345.
12 Curry, A. J., Portig, I., Goodall, J. C., Kirkpatrick, P. J. and Gaston,
J. S. 2000. T lymphocyte lines isolated from atheromatous plaque
contain cells capable of responding to Chlamydia antigens.
Clin. Exp. Immunol. 121:261.
13 Saren, A., Pascolo, S., Stevanovic, S. et al. 2002. Identification of
Chlamydia pneumoniae-derived mouse CD8 epitopes. Infect.
Immun. 70:3336.
14 Kornak, J. M., Kuo, C. C. and Campbell, L. A. 1991. Sequence
analysis of the gene encoding the Chlamydia pneumoniae DnaK
protein homolog. Infect. Immun. 59:721.
15 Wizel, B., Starcher, B. C., Samten, B. et al. 2002. Multiple
Chlamydia pneumoniae antigens prime CD8+ Tc1 responses
that inhibit intracellular growth of this vacuolar pathogen.
J. Immunol. 169:2524.
16 Lamb, D. J., El Sankary, W. and Ferns, G. A. 2003. Molecular
mimicry in atherosclerosis: a role for heat shock proteins in
immunisation. Atherosclerosis 167:177.
17 Mayr, M., Metzler, B., Kiechl, S. et al. 1999. Endothelial cytotoxicity
mediated by serum antibodies to heat shock proteins of
Escherichia coli and Chlamydia pneumoniae: immune reactions
to heat shock proteins as a possible link between infection and
atherosclerosis. Circulation 99:1560.
596 HLA-A2-restricted T cells against Cpn
18 Pascolo, S., Bervas, N., Ure, J. M., Smith, A. G., Lemonnier, F. A.
and Perarnau, B. 1997. HLA-A2.1-restricted education and
cytolytic activity of CD8(+) T lymphocytes from beta2 micro-
globulin (beta2m) HLA-A2.1 monochain transgenic H-2Db beta2m
double knockout mice. J. Exp. Med. 185:2043.
19 Guermonprez, P., Saveanu, L., Kleijmeer, M., Davoust, J., Van
Endert, P. and Amigorena, S. 2003. ER-phagosome fusion defines
an MHC class I cross-presentation compartment in dendritic cells.
Nature 425:397.
20 Prebeck, S., Kirschning, C., Durr, S. et al. 2001. Predominant role of
toll-like receptor 2 versus 4 in Chlamydia pneumoniae-induced
activation of dendritic cells. J. Immunol. 167:3316.
21 Bachmaier, K., Neu, N., de la Maza, L. M., Pal, S., Hessel, A. and
Penninger, J. M. 1999. Chlamydia infections and heart disease
linked through antigenic mimicry. Science 283:1335.
22 Conant, S. B. and Swanborg, R. H. 2003. MHC class II peptide
flanking residues of exogenous antigens influence recognition by
autoreactive T cells. Autoimmun. Rev. 2:8.
23 Schirmbeck, R., Stober, D., El Kholy, S., Riedl, P. and Reimann, J.
2002. The immunodominant, Ld-restricted T cell response to
hepatitis B surface antigen (HBsAg) efficiently suppresses T cell
priming to multiple Dd-, Kd-, and Kb-restricted HBsAg epitopes.
J. Immunol. 168:6253.
24 Rammensee, H., Bachmann, J., Emmerich, N. P., Bachor, O. A.
and Stevanovic, S. 1999. SYFPEITHI: database for MHC ligands
and peptide motifs. Immunogenetics 50:213.
25 Milich, D. R., Hughes, J. L., McLachlan, A., Thornton, G. B. and
Moriarty, A. 1988. Hepatitis B synthetic immunogen comprised
of nucleocapsid T-cell sites and an envelope B-cell epitope.
Proc. Natl Acad. Sci. USA 85:1610.
26 Bonanomi, A., Dohm, C., Rickenbach, Z. et al.. 2003. Monitoring
intracellular replication of Chlamydophila (Chlamydia) pneumo-
niae in cell cultures and comparing clinical samples by real-time
PCR. Diagn. Microbiol. Infect. Dis. 46:39.
27 Altman, J. D., Moss, P. A., Goulder, P. J. et al. 1996. Phenotypic
analysis of antigen-specific T lymphocytes. Science 274:94.
28 Wills, M. R., Carmichael, A. J., Mynard, K. et al. 1996. The human
cytotoxic T-lymphocyte (CTL) response to cytomegalovirus is
dominated by structural protein pp65: frequency, specificity, and
T-cell receptor usage of pp65-specific CTL. J. Virol. 70:7569.
HLA-A2-restricted T cells against Cpn 597
